Sandra M E Geurts
Overview
Explore the profile of Sandra M E Geurts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lenaerts M, van Amstel F, Mottaghy F, Geurts S, Tjan-Heijnen V, Smidt M, et al.
Nucl Med Commun
. 2025 Feb;
PMID: 39998813
The objective is to assess whether the degree of metabolic uptake of the primary tumor and axillary lymph nodes (ALNs) on baseline [18F] fluorodeoxyglucose ([18F]FDG) PET/CT is associated with the...
2.
de Wilde A, de Jong E, Bruno M, Besselink M, van der Geest L, Geurts S, et al.
Ann Surg
. 2024 Oct;
PMID: 39471092
Objective: To evaluate treatment outcomes, overall survival (OS), and prognostic factors for OS in patients diagnosed with T1 ampullary cancer. Background: Ampullary cancer is a rare gastrointestinal malignancy with limited...
3.
Lammers S, Geurts S, Hermans K, van Hellemond I, Swinkels A, Smorenburg C, et al.
Breast Cancer Res Treat
. 2024 Jun;
208(1):179-192.
PMID: 38940981
Purpose: Patients with chemotherapy-induced ovarian function failure (CIOFF) may experience ovarian function recovery (OFR). Earlier, we showed that OFR during treatment with anastrozole impacted the prognosis of hormone receptor-positive (HR+)...
4.
Geurts S, Ibragimova K, Ding N, Meegdes M, Erdkamp F, Heijns J, et al.
Breast Cancer Res Treat
. 2024 Feb;
205(2):287-302.
PMID: 38381274
Purpose: The aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer...
5.
de Wilde A, de Jong E, Gurusamy K, Abu Hilal M, Besselink M, Dewulf M, et al.
Br J Surg
. 2024 Jan;
111(1).
PMID: 38198159
Background: Differentiation between adenomas and carcinomas of the ampulla of Vater is crucial for therapy and prognosis. This was a systematic review of the literature on the accuracy of diagnostic...
6.
van de Weerd C, Geurts S, Vercoulen R, van Veggel I, Brands M, Marres H, et al.
Eur J Surg Oncol
. 2023 Dec;
50(1):107304.
PMID: 38043360
Introduction: The benefits of routine follow-up after treatment of primary laryngeal squamous cell carcinoma (LSCC) remain disputed. Guidelines worldwide are consensus-based, and evidence for specific subgroups is lacking. This study...
7.
Ibragimova K, Geurts S, Laczko D, Meegdes M, Erdkamp F, Heijns J, et al.
Clin Breast Cancer
. 2023 Nov;
24(2):103-111.
PMID: 38007349
Background: This study aims to explore whether first-line pertuzumab use modifies the effect of prior use of (neo-) adjuvant trastuzumab on the PFS of first-line HER2-targeted therapy in patients with...
8.
Lammers S, Geurts S, van Hellemond I, Swinkels A, Smorenburg C, van der Sangen M, et al.
JNCI Cancer Spectr
. 2023 Nov;
7(6).
PMID: 37991939
Background: Obesity has been associated with an adverse prognosis and reduced efficacy of endocrine therapy in patients with hormone receptor-positive (HR+) breast cancer (BC). This study determines the prognostic and...
9.
Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors
Meegdes M, van der Velde M, Geurts S, van Kats M, Dercksen M, Tjan-Heijnen V
J Chemother
. 2023 Nov;
36(4):343-350.
PMID: 37946508
There is an ongoing clinical dilemma of how best to treat patients who present themselves with visceral crisis. The time needed to undo the state of visceral crisis is the...
10.
Lammers S, Thurisch H, Vriens I, Meegdes M, Engelen S, Erdkamp F, et al.
Breast Cancer Res Treat
. 2023 Oct;
203(2):339-349.
PMID: 37878148
Purpose: This study determines the prognostic impact of body mass index (BMI) in patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced (i.e., metastatic) breast cancer (ABC). Methods: All...